tbuckley/cabot-search huggingface dataset:
Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study
Authors: P. Broadhurst, H. Toyoda, T. Kumada, N. Schweitzer, A. Vogel, J. Benckert, T. Berg, J. Best, A. Dechêne, A. Weinmann, P. Galle, W. Yeo, S.L. Chan, S. Berhane, D. Palmer, T. Cross, N. Stern, H. Reeves, P. Johnson
Journal: Journal of Hepatology (2017)
Experience of Conventional Cytogenetics in Elderly Cytopenic Indian Patients Suspected with Myelodysplastic Syndromes
Authors: Bani Bandana Ganguly, Mandal Shouvik, Nitin N Kadam, Debasis Banerjee, Sharmila Chandra, Tuphan Kanti Dolai, Mohan Agarwal
Journal: Blood (2016)
NorUDCA improves liver injury and metabolic situation in mouse models of obesity and steatosis
Authors: D. Steinacher, T. Claudel, J. Grießner, E. Einwallner, M.C. Rühlemann, O. Ronda, F.-A. Heinsen, T. Stojakovic, H. Scharnagl, H.J. Verkade, W.E. Haubensak, M. Trauner
Journal: Journal of Hepatology (2017)
B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cholangitis: a randomised controlled trial (RITPBC)
Authors: L. Jopson, A. Khanna, A. Blamire, J. Newton, J. Palmer, A. Bryant, D. Howel, A. Steel, J. Wilkinson, D. Jones
Journal: Journal of Hepatology (2017)
Impact of treatment with Telmisartan plus Propranolol on liver tight junctions in MDR2 -/- knockout mice
Authors: S. Schulte, S. Mende, I. Strack, M. Odenthal, S. Zweerink, D. Nierhoff, H.-P. Dienes, T. Goeser, H.-M. Steffen, U. Toex
Journal: Journal of Hepatology (2017)
CDC Grand Rounds: Public Health Strategies to Prevent and Treat Strokes
Authors: Mary G. George, Leah Fischer, Walter Koroshetz, Cheryl Bushnell, Michael Frankel, Jennifer Foltz, Phoebe G. Thorpe
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Worldwide, stroke is the second leading cause of death and a leading cause of serious long-term disability. In the United States, nearly 800,000 strokes occur each year; thus stroke is the fifth leading cause of death overall and the fourth leading cause of death among women (1). Major advances in stroke prevention through treatment of known risk factors has led to stroke being considered largely preventable. For example, in the United States, stroke mortality rates have declined 70% over the past 50 years, in large part because of important reductions in hypertension, tobacco smoking, and more recently, increased use of anticoagulation for atrial fibrillation (2,3). Although the reduction in stroke mortality is recognized as one of the 10 great public health achievements of the 20th century (4), gains can still be made. Approximately 80% of strokes could be prevented by screening for and addressing known risks with measures such as improving hypertension control, smoking cessation, diabetes prevention, cholesterol management, increasing use of anticoagulation for atrial fibrillation, and eliminating excessive alcohol consumption (5,6).
Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4)
Authors: S.M. El-Nahaas, M. Said, Z.A. Soliman, Y. Saad, M. El-Serafy, A. Yosry, I. Waked, G. Esmat, W. Doss
Journal: Journal of Hepatology (2017)
Legal Complexities of Global Vaccine Compensation Systems
Authors: Anna C. Mastroianni, Leslie Meltzer Henry
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacological inhibition of Axl tyrosine kinase as a novel therapeutic strategy in hepatocellular carcinoma.
Authors: David James Pinato, Sebastian Trousil, Matthew Caley, Francesco A Mauri, Eric Aboagye, Rohini Sharma
Journal: Journal of Clinical Oncology (2015)

e15152 Background: Aberrant activation of Axl tyrosine kinase and its ligand Gas-6 is implicated in the progression of hepatocellular carcinoma (HCC) by promoting cell survival, proliferation and motility. We explored the biological significance and preclinical efficacy of Axl inhibition as a therapeutic strategy in HCC. Methods: We confirmed Axl overexpression in a panel of immortalized HCC cell lines and in human tissue using immunohistochemistry. We tested pharmacological inhibition with Axl inhibitor R428 and RNA interference on cell cytotoxicity and apoptisis assays, cell cycle analysis, random motility assays, western blot (WB) and 18F-FDG uptake studies. Results: Axl mRNA overexpression was found in 13/28 cell lines and negatively correlated with E-cadherin expression (p = 0.001). In a restricted panel of 7 lines, WB confirmed Axl to correlate positively with Vimentin and negatively with E-cadherin expression, consistent with a mesenchymal phenotype. A significant overexpression gradient for Axl was found comparing normal livers, cirrhotic nodules with HCC samples, 60% of which showed high immunolabeling (n = 10 each group). Gas-6 expression was restricted to Kupffer cells. Across a panel of cell lines, R428 was associated with GI50values between 1.5-3.6 μM. In Axl high expressing SkHep-1 cells, we observed that R428 induced G1-cycle arrest and significant reduction in 18FDG uptake, consistent with drug-induced antiproliferative effects. Combination treatment with sorafenib and R428 yielded synergistic cytotoxic effect (combination index: 0.32) in two independent Axl overexpressing lines. Conclusions: Suppression of Axl-dependent signaling modulates several aspects of the transformed phenotype in immortalized HCC cell lines including proliferation, motility and survival. Our data provide a pre-clinical rationale for the development of Axl inhibitors as a novel therapeutic strategy in HCC.
The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients
Authors: G. Marasco, A. Colecchia, A. Colli, G. Casazza, F. Ravaioli, A. Cucchetti, M. Cescon, A.D. Pinna, D. Festi
Journal: Journal of Hepatology (2017)
Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).
Authors: Suresh Senan, Anthony M. Brade, Luhua Wang, Johan F. Vansteenkiste, Shaker R. Dakhil, Bonne Biesma, Maite Martinez Aguillo, Joachim Aerts, Ramaswamy Govindan, Belén Rubio-Viqueira, Conrad R. Lewanski, David R. Gandara, Hak Choy, Tony Mok, Anwar Hossain, Neill Allan Iscoe, Joseph Treat, Andrew G. Koustenis, Nadia Chouaki, Everett E. Vokes
Journal: Journal of Clinical Oncology (2015)

7506 Background: Efficacy and safety of concurrent Pem+Cis and TRT followed by consolidation Pem vs other CTX regimens were evaluated; interim safety results (concurrent phase) were presented previously (Vokes et al. 2013). Methods: Five hundred and ninety-eight patients (pts) with stage III unresectable nsNSCLC were randomized 1:1 to Pem+Cis (Pem 500 mg/m2+Cis 75 mg/m2, intravenously, plus vitamins) plus concurrent TRT (66.0 Gy) every 21 days (q21d) x 3 cycles followed by Pem consolidation q21d x 4 cycles vs the control arm Eto+Cis (Eto 50 mg/m2+Cis 50 mg/m2, intravenously) plus concurrent TRT (66.0 Gy) q28d x 2 cycles followed by 2 cycles of a consolidation CTX of choice: Cis+Eto, Cis+vinorelbine, or paclitaxel+carboplatin. The primary objective was OS. Progression-free survival (PFS), objective response rate (ORR), and safety were key secondary objectives. This superiority trial was designed to achieve 80% power, assuming an OS HR of 0.74 with 355 events at 0.05 α (two-sided) using a log-rank test. Results: Five hundred and fifty-five pts were treated: 283 Pem+Cis, 272 Eto+Cis. Baseline characteristics were balanced between arms (Pem+Cis/Eto+Cis): median age, 59.5/58.7; female, 41.2%/40.1%; stage IIIB, 53.5%/51.2%; positron emission tomography scans, 83.1%/81.1%; and Eastern Cooperative Oncology Group performance status 1, 50.5%/50.2%. Pem+Cis vs Eto+Cis median OS was 26.8 vs 25.0 mos (HR 0.98; 95% CI: 0.79, 1.20; p = 0.831) and median PFS was 11.4 vs 9.8 mos (HR 0.86; 95% CI: 0.71, 1.04; p = 0.130). Pem+Cis/Eto+Cis ORR was 35.9%/33.0% (p = 0.458) and disease control rate was 80.7%/70.7% (p = 0.004). Possibly related grade (G) 3/4 toxicities (Pem+Cis vs Eto+Cis) occurred in 64.0% vs 76.8% of pts (p = 0.001). The Pem+Cis arm had a lower incidence of possibly related G3/4 neutropenia/granulocytopenia vs the Eto+Cis arm: 24.4% vs 44.5% of pts (p < 0.001). Pem+Cis vs Eto+Cis rates of G3/4 pneumonitis/pulmonary infiltrates and esophagitis were 1.8% vs 2.6% and 15.5% vs 20.6%, respectively. Conclusions: The Pem+Cis arm did not improve OS vs the control arm, but did have a better safety profile than the Eto+Cis arm. Clinical trial information: NCT00686959.
Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein as a serum biomarker for disease severity in non-alcoholic fatty liver disease
Authors: L.L. Lai, W.K. Chan, P. Sthaneshwar, N.R.N. Mustapha, K.L. Goh, S. Mahadeva
Journal: Journal of Hepatology (2017)
Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in obese patients with non-alcoholic fatty liver disease
Authors: S. Lefere, F. Van de Velde, L. Devisscher, M. Bekaert, S. Raevens, X. Verhelst, Y. Van Nieuwenhove, M. Praet, A. Hoorens, C. Van Steenkiste, H. Van Vlierberghe, B. Lapauw, A. Geerts
Journal: Journal of Hepatology (2017)
Slow low-dose continuous albumin, furosemide ± terlipressin and N-acetylcystine infusion in severe alcoholic hepatitis safely mobilizes ascites in acute on chronic liver failure with organ failure(s) and improves 28-day survival
Authors: G. Pandey, A. Nehra, A. Verma, S. Mohindra, U.C. Ghoshal, K. Kumar, P. Mishra, V.A. Saraswat
Journal: Journal of Hepatology (2017)
New molecular classification of hepatoblastoma through an integrative genomic and transcriptomic study
Authors: M. Simon-Coma, N. Akers, D. Sia, L. Royo, J. Carrillo, K. Pedersen, M. Mallo, M. Arnal, O. Kuchuk, M. Gambato, S. Cairo, M.A. Buendia, M. Vázquez, L. Nonell, M. Sala, M.R. Sarrias, B. Losic, J.M. Llovet, C. Armengol
Journal: Journal of Hepatology (2017)
A phase II study of the efficacy and toxicity of alemtuzumab for the therapy of human T cell lymphotrophic virus-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL)
Authors: K. Sharma, J. Janik, D. O’Mahony, D. O’Hagan, W. W. Gao, G. H. Wharfe, B. E. Cranston, T. A. Waldmann, J. C. Morris
Journal: Journal of Clinical Oncology (2006)

2535 Background: HTLV-1-associated ATL is an aggressive lymphoproliferative disorder with limited effective therapy. Alemtuzumab is a humanized monoclonal antibody directed against CD52. High levels of CD52 are expressed on the surface of ATL cells. Preclinical studies in the MET-1 mouse model of ATL showed alemtuzumab to be highly active. Methods: A single institution open-label phase II study examining the response and toxicity of alemtuzumab in patients with ATL. Eligibility criteria: HTLV-1-associated ATL (chronic, acute and lymphoma type), ≥10% CD52+ malignant cells, measurable disease, age ≥18 years, AGC ≥1000/μL, platelets ≥50,000/μL, adequate physiologic status and informed consent. Results: Ten (10) patients, 6 with leukemia, 4 with lymphoma, 8 Afro-Caribbean, 1 African-American and 1 Japanese, 7 women, 3 men, median age 49 years (range, 36–62), all having received previous treatments including CHOP (7), other monoclonal antibodies (5), radioimmunotherapy (2), and radiation (1), median WBC 48,500/μL (leukemia Pts.) received alemtuzumab standard induction followed by 30 mg 3 times weekly for a minimum of 4 weeks and maximum of 12 weeks. All patients experienced infusion reactions (grade, 1–3) including hypotension, fever, rigors, chills, pruritus and urticaria; however, no patient required discontinuation of treatment. All patients developed grade 4 lymphopenia, and transient cytomegalovirus (CMV) antigenemia. Four (4) patients with leukemia responded (1 CR, 3 PR). No patient with lymphoma responded. Conclusions: Alemtuzumab has antitumor activity in HTLV-1-associated adult T cell leukemia and is well tolerated. Lymphomatous ATL appears unresponsive to alemtuzumab. The reason for this is unknown; however, antibody levels achieved in lymph nodes may be suboptimal. Accrual continues. No significant financial relationships to disclose.
Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models
Authors: U. Weinberg, T. Voloshin, O.T. Yitzaki, N. Kaynan, M. Giladi, A. Shteingauz, M. Munster, S. Cahal, E.D. Kirson, Y. Palti
Journal: Annals of Oncology (2017)
Man stops stuttering with alcohol dependence drug
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

The muscle relaxant drug baclofen may help people who stutter, researchers have said, after a man given the drug in a clinical trial on alcohol dependence spoke fluently and then stuttered again when he stopped taking it.

Reporting their findings in BMJ Case Reports ,1 researchers from the Netherlands warned that the result would need to be confirmed in clinical trials, but they cited plausible biological reasons for their observations.

Baclofen is a muscle relaxant used to treat the muscle spasticity caused by conditions such as multiple sclerosis and spinal cord diseases. It …
Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip
Authors: Samira Musah, Akiko Mammoto, Thomas C. Ferrante, Sauveur S. F. Jeanty, Mariko Hirano-Kobayashi, Tadanori Mammoto, Kristen Roberts, Seyoon Chung, Richard Novak, Miles Ingram, Tohid Fatanat-Didar, Sandeep Koshy, James C. Weaver, George M. Church, Donald E. Ingber
Journal: Nature Biomedical Engineering (2017)
Al Rhazes and the Beginning of the End of Smallpox
Authors: Isabelle C. Band, Martin Reichel
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
A feasibility trial evaluating the addition of nivolumab to standard first-line chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: The ETOP 6-14 NICOLAS trial
Authors: S. Peters, R.A. Stahel, M. Kassapian, M. Guckenberger, E. Felip, A.J. De Langen, R.M. Huber, H. Roschitzki-Voser, A.-C. Piguet, D. De Ruysscher
Journal: Annals of Oncology (2017)
A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study
Authors: Sara Ghorashian, Anne Marijn Kramer, Sarah Jayne Albon, Catherine Irving, Lucas Chan, Fernanda Castro, Bilyana Popova, Kim Champion, Gary Wright, Hong Zhan, Waseem Qasim, Robert Wynn, Rachael Hough, Farzin Farzaneh, Martin A Pule, Persis J Amrolia
Journal: Blood (2016)
Polyunsaturated fatty acids and eicosanoids in ascites serve as potential new biomarkers for complications in liver cirrhosis
Authors: C. Engelmann, V. Degenhardt, J. Dorow, S. Krohn, A. Herber, N. Mueller, T. Herta, J. Thiery, U. Ceglarek, T. Berg
Journal: Journal of Hepatology (2017)
MAP4/OP18 mRNA expression predicts progression in patients treated with vinorelbine plus carbolpatin in advanced lung cancer patients in a Multicenter trial
Authors: J. Galan, S. del Barco, M. Mendez, G. Esquerdo, M. G. Huarriz, E. Bandres, M. C. Gil, A. B. Paules, J. Gayo, J. Garcia- Foncillas
Journal: Journal of Clinical Oncology (2007)

14088 Background: Non-small-cell lung cancer patients with locally advanced or metastatic disease at the time of diagnosis show marginal response to chemotherapy in terms of tumor shrinkage, time to progression and median survival. MAP4 and stahmin have been previously reported as potential markers of resistance to treatment based on microtubule-destabilizing agents. Methods: In this multicenter study, we have used quantitative PCR to analyse expression of MAP4, stathmin, beta-tubulin III, BRCA1 and ERCC1 in mRNA isolated from peripheral blood samples of 51 non-small-cell lung cancer patients treated with vinorelbine/carboplatin. Results: In a preliminary set, 29 patients with stage IIIB and IV were analyzed. Lower levels of MAP4/OP18 mRNA expression are statistically related with response to vinorelbine-based treatment (p=0,029). This significant relationship is maintained in a second analysis after third cycle of treatment (p=0,032). Higher levels of MAP4/op18 were associated with a lower TTP (p=0,05). Conclusions: Our preliminary results suggest that the ratio MAP4/OP18 may be a good predictor of response for patients with non-small-cell lung cancer treated with vinorelbine-based chemotherapy. No significant financial relationships to disclose.
Vitamin D levels and susceptibility to asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian randomization study
Authors: Despoina Manousaki, Lavinia Paternoster, Marie Standl, Miriam F. Moffatt, Martin Farrall, Emmanuelle Bouzigon, David P. Strachan, Florence Demenais, Mark Lathrop, William O. C. M. Cookson, J. Brent Richards
Journal: PLoS Medicine (2017)

Background Low circulating vitamin D levels have been associated with risk of asthma, atopic dermatitis, and elevated total immunoglobulin E (IgE). These epidemiological associations, if true, would have public health importance, since vitamin D insufficiency is common and correctable. Methods and findings We aimed to test whether genetically lowered vitamin D levels were associated with risk of asthma, atopic dermatitis, or elevated serum IgE levels, using Mendelian randomization (MR) methodology to control bias owing to confounding and reverse causation. The study employed data from the UK Biobank resource and from the SUNLIGHT, GABRIEL and EAGLE eczema consortia. Using four single-nucleotide polymorphisms (SNPs) strongly associated with 25-hydroxyvitamin D (25OHD) levels in 33,996 individuals, we conducted MR studies to estimate the effect of lowered 25OHD on the risk of asthma (n = 146,761), childhood onset asthma (n = 15,008), atopic dermatitis (n = 40,835), and elevated IgE level (n = 12,853) and tested MR assumptions in sensitivity analyses. None of the four 25OHD-lowering alleles were associated with asthma, atopic dermatitis, or elevated IgE levels (p ≥ 0.2). The MR odds ratio per standard deviation decrease in log-transformed 25OHD was 1.03 (95% confidence interval [CI] 0.90–1.19, p = 0.63) for asthma, 0.95 (95% CI 0.69–1.31, p = 0.76) for childhood-onset asthma, and 1.12 (95% CI 0.92–1.37, p = 0.27) for atopic dermatitis, and the effect size on log-transformed IgE levels was −0.40 (95% CI −1.65 to 0.85, p = 0.54). These results persisted in sensitivity analyses assessing population stratification and pleiotropy and vitamin D synthesis and metabolism pathways. The main limitations of this study are that the findings do not exclude an association between the studied outcomes and 1,25-dihydoxyvitamin D, the active form of vitamin D, the study was underpowered to detect effects smaller than an OR of 1.33 for childhood asthma, and the analyses were restricted to white populations of European ancestry. This research has been conducted using the UK Biobank Resource and data from the SUNLIGHT, GABRIEL and EAGLE Eczema consortia. Conclusions In this study, we found no evidence that genetically determined reduction in 25OHD levels conferred an increased risk of asthma, atopic dermatitis, or elevated total serum IgE, suggesting that efforts to increase vitamin D are unlikely to reduce risks of atopic disease.
Ingestion of wheat amylase trypsin inhibitors promotes a proinflammatory liver and adipose tissue phenotype in diet induced non-alcoholic fatty liver disease in mice
Authors: M. Ashfaq-Khan, M. Aslam, M.A. Qureshi, S.Y. Weng, X. Wang, V. Zevallos, Y.O. Kim, D. Schuppan
Journal: Journal of Hepatology (2017)